Skip to main content

OTCMKTS:TRUMY - Terumo Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$35.75
▼ -0.78 (-2.14%)
1 month | 3 months | 12 months
Get New Terumo Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRUMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRUMY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Terumo in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $35.75.

Hold

The current consensus among 2 polled investment analysts is to hold stock in Terumo.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/14/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral
i
7/22/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
i
(Data available from 5/18/2016 forward)
Terumo logo
Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. The company operates through three segments: Cardiac and Vascular Company, General Hospital Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stent, intravascular ultrasound systems, drug-eluting stents, imaging catheters, and others; coils and stents for treating cerebral aneurysm, aspiration catheters and clot retrievers for treating ischemic stroke, and others; oxygenators, flow diverters, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The General Hospital Company segment provides infusion pumps, syringe pumps, solution sets, syringes, I.V. solutions, pain management products, nutritious food, adhesion barriers, blood glucose monitoring systems, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, automated blood collection systems, automated blood component processing systems, pathogen reduction technology, automated centrifugal apheresis systems, cell expansion system, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $35.75
$35.33
$35.96

50 Day Range

MA: $37.33
$35.35
$38.80

52 Week Range

Now: $35.75
$34.20
$44.76

Volume

25,492 shs

Average Volume

31,369 shs

Market Capitalization

$27.15 billion

P/E Ratio

34.71

Dividend Yield

0.52%

Beta

0.38

Frequently Asked Questions

What sell-side analysts currently cover shares of Terumo?

The following Wall Street analysts have issued stock ratings on Terumo in the last twelve months: Credit Suisse Group AG, Jefferies Financial Group Inc., and Zacks Investment Research.
View the latest analyst ratings for TRUMY.

What is the current price target for Terumo?

0 Wall Street analysts have set twelve-month price targets for Terumo in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Terumo in the next year.
View the latest price targets for TRUMY.

What is the current consensus analyst rating for Terumo?

Terumo currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TRUMY, but not buy more shares or sell existing shares.
View the latest ratings for TRUMY.

What other companies compete with Terumo?

Other companies that are similar to Terumo include Henry Schein, Patterson Companies, Owens & Minor, BrewBilt Manufacturing, Fuse Medical and InternetArray.

How do I contact Terumo's investor relations team?

Terumo's physical mailing address is 2-44-1 Hatagaya Shibuya-ku, Tokyo M0, 151-0072. The company's listed phone number is (133) 374-8111 and its investor relations email address is [email protected] The official website for Terumo is www.terumo.co.jp.